WellTrackONE, LLC is a population health management company based in Hilton Head Island, South Carolina, with an additional office in New York, New York. Founded in 2010, it specializes in providing wellness programs to healthcare providers, including rural health clinics and integrated delivery networks. The company focuses on administering Medicare Annual Wellness Visits, offering clinical risk management services that generate comprehensive baseline reports detailing modifiable risk factors, preventative goals, and measurable data. WellTrackONE supports healthcare professionals by scheduling, screening, and documenting wellness visits, while also providing critical data for accountable care organizations and helping payers maintain compliance with clinical indicators and quality measures. Through its customized wellness solutions, WellTrackONE aims to enhance patient care and improve health outcomes for Medicare patients across the United States.
Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
Wildflower Health, Inc. is a San Francisco-based company that provides smartphone-based health programs designed to help healthcare payers connect with families across the United States. Its flagship offering, Due Date Plus, is a maternity program that engages women in early pregnancy and facilitates connections with healthcare providers or care managers. Additionally, Wildflower Health offers GROW, a family health program that addresses the needs of mothers and pediatric health. The company delivers tailored health milestones for families based on age and gender, along with features such as client resource integrations, on-device messaging, appointment reminders, health risk assessments, and clinical program referrals. Founded in 2012, Wildflower Health aims to enhance user engagement and improve healthcare experiences through innovative technology and design.
PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
Medikly, Inc. provides a digital marketing platform for healthcare marketers. Its digital marketing platform enables marketers to capture and apply actionable physician intelligence. The company also provides MediklyOS, a solution that enables brands to launch, execute, modify, and measure marketing campaigns; and consulting, support, training, integration, and campaign services. Medikly, Inc. was founded in 2009 and is based in Jersey City, New Jersey.
Claret Medical, Inc. is a cardiovascular medical device company that specializes in developing cerebral vascular protection systems for transcatheter aortic valve implantation and various endovascular procedures. Its flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris that may be dislodged during these procedures. Additionally, the company offers small 6 French catheters that are inserted through an artery in the patient's right arm and guided toward the heart, facilitating the protection of the cerebral vascular system from potential embolic material. Founded in 2009 and based in Santa Rosa, California, Claret Medical operates as a subsidiary of Boston Scientific Corporation, focusing on enhancing patient safety during interventional cardiovascular treatments.
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of patient administered non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Basking Ridge, New Jersey.
MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.
Respiratory Motion, Inc. is a medical device company that specializes in the development and commercialization of respiratory monitoring technologies. Headquartered in Waltham, Massachusetts, the company focuses on its flagship product, ExSpiron, a point-of-care device designed to non-invasively measure and provide quantitative values for key respiratory parameters, including minute ventilation, tidal volume, and respiratory rate. The ExSpiron has received FDA clearance, allowing it to graphically display lung volumes over time, thereby enabling healthcare providers to acquire precise data on patients’ respiratory function. Founded in 2010, Respiratory Motion aims to enhance the standard of care in respiratory monitoring while improving patient safety and outcomes through cost-effective solutions.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
SOLX, Inc. is a medical device company based in Waltham, Massachusetts, specializing in the development of innovative solutions for glaucoma treatment. Founded in 2000, the company focuses on creating products that measure and reduce intraocular pressure (IOP) in the eye. Its flagship product, the SOLX Gold Shunt, is a minimally invasive surgical device designed to facilitate the drainage of fluid from the anterior chamber to the suprachoroidal space, effectively addressing glaucoma while minimizing the risks associated with traditional filtering surgeries, such as bleb-related complications. Through its advancements, SOLX aims to improve the management of glaucoma and enhance patient outcomes.
Precise Light Surgical, Inc. specializes in developing innovative tissue resection solutions for microsurgical procedures. Founded in 2008 and based in California, the company focuses on providing less invasive surgical options that prioritize the preservation of critical anatomy, thereby reducing surgical risks and enhancing patient outcomes. Its technology, which employs flash vaporization, offers precise control for the removal of delicate tissues while safeguarding nerves and blood vessels. This approach is applicable across various medical fields, including plastic surgery, ear, nose, and throat (ENT) surgery, and neurosurgery. By improving surgical precision and reducing recovery time, Precise Light Surgical aims to enhance the overall efficiency and effectiveness of surgical interventions.
Comprehend provides a suite of cloud applications and consulting services that improve the clinical trial process. Their solutions deliver actionable risk and performance insights across studies, systems, sites, and vendors.
It was founded in 2010 and headquartered in Redwood City, California.
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.
Medikly, Inc. provides a digital marketing platform for healthcare marketers. Its digital marketing platform enables marketers to capture and apply actionable physician intelligence. The company also provides MediklyOS, a solution that enables brands to launch, execute, modify, and measure marketing campaigns; and consulting, support, training, integration, and campaign services. Medikly, Inc. was founded in 2009 and is based in Jersey City, New Jersey.
Within3 is a provider of digital collaboration service used to collaborate with healthcare professionals with patients. The company's online discussion platform allows organizations to compliantly engage physicians, nurses, payers, and patients in groups large or small. It leverages the latest social technologies to build private, regulatory compliant programs for advisory boards, clinical trials, and speakers bureaus.
Within3 was founded in 2008 and is headquartered in Lakewood, Ohio.
PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.
Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focusing on the development of biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product, RSLV-125, through preclinical research and into phase IIa clinical trials. Additionally, it has developed RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby preventing interferon activation and mitigating kidney damage. Another product, RSLV-133, is a bi-specific Fc-nuclease fusion protein that combines two distinct nuclease activities into a single drug molecule. Founded in 2010, Resolve Therapeutics is built on the groundbreaking research of Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a mission to improve the lives of lupus patients.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
Achronix Semiconductor Corp., founded in 2004 and headquartered in Santa Clara, California, specializes in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). The company offers a range of products, including Speedster®22i HD devices, which feature up to 1.7 million effective look-up tables (LUTs) and 138 megabits of embedded RAM, and Speedster22i HP devices, which utilize picoPIPE architecture and provide up to 590 thousand effective LUTs with 64 megabits of embedded RAM. Achronix's Speedcore eFPGA IP allows integration into customer system-on-chips (SoCs) for compute and network acceleration. Additionally, the Achronix CAD Environment (ACE) supports FPGA design, while the HD1000 development board is optimized for networking and communication sub-systems. Achronix serves diverse markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Its products are distributed across North America, Europe, Israel, China, and Russia, with research and development facilities also in Bangalore, India.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
TigerConnect is a healthcare communication platform designed to enhance collaboration among healthcare professionals, patients, and care providers. Founded in 2010 and based in Santa Monica, California, the company offers real-time mobile messaging that combines a user-friendly experience with robust security and privacy features. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. The platform facilitates effective communication and workflow integration with critical hospital systems, ultimately aiming to improve productivity, reduce costs, and enhance patient outcomes. TigerConnect's commitment to client success is evident in its comprehensive support services, which assist organizations in optimizing communication workflows.
SOLX, Inc. is a medical device company based in Waltham, Massachusetts, specializing in the development of innovative solutions for glaucoma treatment. Founded in 2000, the company focuses on creating products that measure and reduce intraocular pressure (IOP) in the eye. Its flagship product, the SOLX Gold Shunt, is a minimally invasive surgical device designed to facilitate the drainage of fluid from the anterior chamber to the suprachoroidal space, effectively addressing glaucoma while minimizing the risks associated with traditional filtering surgeries, such as bleb-related complications. Through its advancements, SOLX aims to improve the management of glaucoma and enhance patient outcomes.
Within3 is a provider of digital collaboration service used to collaborate with healthcare professionals with patients. The company's online discussion platform allows organizations to compliantly engage physicians, nurses, payers, and patients in groups large or small. It leverages the latest social technologies to build private, regulatory compliant programs for advisory boards, clinical trials, and speakers bureaus.
Within3 was founded in 2008 and is headquartered in Lakewood, Ohio.
EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.
Resolve Therapeutics, LLC is a clinical-stage biopharmaceutical company based in Seattle, Washington, focusing on the development of biological therapies for autoimmune diseases, particularly systemic lupus erythematosus and Sjögren's syndrome. The company is advancing its lead product, RSLV-125, through preclinical research and into phase IIa clinical trials. Additionally, it has developed RSLV-132, a mono-specific nuclease Fc-fusion protein designed to target and eliminate immune complexes, thereby preventing interferon activation and mitigating kidney damage. Another product, RSLV-133, is a bi-specific Fc-nuclease fusion protein that combines two distinct nuclease activities into a single drug molecule. Founded in 2010, Resolve Therapeutics is built on the groundbreaking research of Dr. Keith Elkon and Dr. Jeff Ledbetter at the University of Washington School of Medicine, with a mission to improve the lives of lupus patients.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
Autonet Mobile, Inc. is a technology company that specializes in internet-based telematics and applications services aimed at enhancing vehicle connectivity in motion. Founded in 2005 and headquartered in Santa Rosa, California, the company offers a suite of products known as Dealer Connect, which automates vehicle health scans, lot tracking, and customer appointment scheduling for automotive dealers. For consumers, Autonet Mobile provides features such as 24/7 WiFi access, vehicle health monitoring, and driver safety applications. The company’s platform serves as a real-time diagnostic and reporting tool, alerting users to routine maintenance needs and transforming standard vehicles into connected cars. Autonet Mobile has established partnerships with several major automotive manufacturers, further solidifying its position in the industry. The company also offers installation, activation, setup, and customer support services for its products. It operates as a subsidiary of Lear Corporation.
Format Dynamics specializes in enhancing the integration of online advertising with print media by optimizing how web pages are printed. The company develops tools that allow advertisers to create new ad inventory by transforming printed web pages into visually appealing formats resembling magazines. This innovation enables advertisers to attach specific printable information and offers directly to onscreen advertisements, thereby expanding revenue opportunities. By improving the user experience and providing targeted advertising solutions, Format Dynamics facilitates a seamless transition from digital content to print, ultimately benefiting both advertisers and consumers.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
EMKinetics, Inc. is a clinical-stage medical technology company based in San Francisco, California, specializing in the development of neuromodulation therapies utilizing its proprietary Transdermal Stimulation (TranStim) technology. This innovative approach aims to provide effective treatment for conditions such as overactive bladder and urinary incontinence by delivering electric pulses that facilitate neuromodulation. Founded in 2006, EMKinetics focuses on advancing its therapies to improve patient outcomes in managing these health issues.
Coapt Systems, Inc. specializes in the design, development, and manufacturing of bio-absorbable implants intended for soft tissue fixation in facial cosmetic surgery. Its product offerings include various fixation devices such as the ENDOTINE Forehead 3.0 and ENDOTINE Midface ST 4.5, which are employed in procedures like forehead lifts, brow lifts, and midface suspensions. The company also provides surgical instruments and tools, including insertion kits and manual drills, to facilitate the use of its implants. Coapt Systems aims to support surgeons in achieving effective and secure tissue fixation during surgical procedures, enhancing outcomes for patients undergoing cosmetic interventions.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
A payment platform to handle transactions in online games, digital media and social networks
Achronix Semiconductor Corp., founded in 2004 and headquartered in Santa Clara, California, specializes in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). The company offers a range of products, including Speedster®22i HD devices, which feature up to 1.7 million effective look-up tables (LUTs) and 138 megabits of embedded RAM, and Speedster22i HP devices, which utilize picoPIPE architecture and provide up to 590 thousand effective LUTs with 64 megabits of embedded RAM. Achronix's Speedcore eFPGA IP allows integration into customer system-on-chips (SoCs) for compute and network acceleration. Additionally, the Achronix CAD Environment (ACE) supports FPGA design, while the HD1000 development board is optimized for networking and communication sub-systems. Achronix serves diverse markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Its products are distributed across North America, Europe, Israel, China, and Russia, with research and development facilities also in Bangalore, India.
Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.
A payment platform to handle transactions in online games, digital media and social networks
Transave, Inc., a biotechnology company, develops inhaled pharmaceuticals for the treatment of lung diseases. The company’s liposomal technology allows the release of drug in the lung's microenvironment. Its products also include Arikace for the treatment of gram-negative lung infections and pseudomonas infections in cystic fibrosis patients; and cisplatin lipid complex for the treatment of cancers affecting the lungs. Transave, Inc. was founded in 1997 and is headquartered in Monmouth Junction, New Jersey. As of December 1, 2010, Transave, Inc. operates as a subsidiary of Insmed Incorporated.
WIRECOM Technologies is a French company with state-of-the-art technology and an experience of over 10 years. Committed to sustainable development and the fight against global warming, WIRECOM Technologies designs and develops solutions to optimise energy efficiency in buildings and residences
A payment platform to handle transactions in online games, digital media and social networks
GoCrossCampus, initially the flagship product of GXStudios, was developed by a group of students from Yale and Columbia between 2007 and 2010. It emerged as a pioneering social gaming platform, engaging hundreds of thousands of college students in a rivalry-based game of territorial conquest. Players formed teams representing different colleges or affinity groups, competing to conquer each other's campuses through strategic gameplay that included real-time interactions and recruitment efforts. The game's popularity extended beyond college campuses, with GXStudios also creating GoCrossOffice, a variant designed for corporate team-building activities aimed at enhancing morale and communication within virtual workforces. Despite its initial success, the company faced challenges during the 2008-2009 recession, leading to the decision to wind down operations and license its intellectual property. The founders were part of the Yale Entrepreneurial Institute, which continues to support startup ventures today.
IGA serves advertisers and video game publishers looking to include marketing messages within console and PC games. IGA's roster of publisher partners includes [Electronic Arts](http://www.crunchbase.com/organization/electronic-arts), Valve, and Atari among others. The company competes with [Massive](http://www.crunchbase.com/organization/massive) and [AdScape](http://www.crunchbase.com/organization/adscape), two video game ad agencies that were acquired by [Microsoft](http://www.crunchbase.com/organization/microsoft) and [Google](http://www.crunchbase.com/organization/google) respectively.
Gentis is a company focused on developing minimally invasive biomaterials-based products aimed at treating early-stage degeneration of the spine. Founded in 2000 and headquartered in Wayne, Pennsylvania, the company's flagship product, DiscCell, is an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material designed to augment or replace the diseased nucleus pulposus of the spinal disc. This innovative solution helps patients prevent the recurrence of back or leg pain at the treatment site, addressing a significant need in spinal healthcare.
Biolex Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic proteins and monoclonal antibodies using its patented LEX System. This innovative technology genetically transforms the aquatic plant Lemna to facilitate the production of biologic product candidates that are challenging to manufacture. Biolex's primary product is designed to address the needs of patients afflicted with Hepatitis C, aiming to improve treatment outcomes through enhanced efficacy and potency of its therapeutic offerings.
Lamina, a Westhampton, N.J.-based LED developer.
Xoft, Inc. develops electronic brachytherapy (eBx) systems for radiation oncology applications. It offers Axxent Controller that utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed. The company also provides Axxent balloon applicator, a treatment solution for accelerated partial breast irradiation; Axxent vaginal applicator that enables radiation oncologists to perform vaginal brachytherapy; and Axxent surface applicator that enables radiation oncologists to treat surface lesions. In addition, it offers accessories, such as physics accessory kits, personnel protective shields, procedure accessory packs, patient care kits, applicator clamp and base plates, and vacuum pumps, as well as FlexiShield, which drapes over the patient treatment area to reduce radiation transmission to nearby healthy tissue and organs. The company's products are used to treat early stage breast cancer, skin cancer, and endometrial cancer. It offers its products through physicians and distributors in Europe. Xoft, Inc. was formerly known as Xoft microTube, Inc. and changed its name in September 2004. The company was founded in 1998 and is based in Sunnyvale, California.
Coapt Systems, Inc. specializes in the design, development, and manufacturing of bio-absorbable implants intended for soft tissue fixation in facial cosmetic surgery. Its product offerings include various fixation devices such as the ENDOTINE Forehead 3.0 and ENDOTINE Midface ST 4.5, which are employed in procedures like forehead lifts, brow lifts, and midface suspensions. The company also provides surgical instruments and tools, including insertion kits and manual drills, to facilitate the use of its implants. Coapt Systems aims to support surgeons in achieving effective and secure tissue fixation during surgical procedures, enhancing outcomes for patients undergoing cosmetic interventions.
Sanarus Medical, Inc. specializes in developing and marketing minimally invasive devices for the diagnosis and treatment of breast tumors. The company offers the Visica Treatment System, which utilizes cryoablation to treat breast fibroadenomas, and the Cassi II rotational core biopsy system, an automated device designed for obtaining contiguous biopsy samples. Additionally, Sanarus provides the ImarC tissue marker system, which includes breast tissue markers visible under various imaging modalities. Founded in 1999 and headquartered in Pleasanton, California, Sanarus Medical focuses on providing innovative solutions for both cancerous and non-cancerous breast conditions.
Trellis Bioscience LLC is a biotechnology company that focuses on discovering and developing human antibody therapeutics for infectious diseases and oncology. The company utilizes its proprietary CellSpot technology platform to identify rare and naturally optimized antibodies derived from healthy human donor blood cells. This platform enables the discovery of therapeutic monoclonal antibodies targeting various infectious diseases, as well as cancer immune checkpoint targets, including those associated with difficult-to-treat cancers. By leveraging its advanced cell biology technology, Trellis Bioscience provides a single-cell level analysis for monitoring diverse cell types and evaluating the effects of potential therapeutic interventions. Founded in 1998 and headquartered in Redwood City, California, Trellis Bioscience aims to offer safe and effective medical alternatives for patients by harnessing the power of the human immune system.
Achronix Semiconductor Corp., founded in 2004 and headquartered in Santa Clara, California, specializes in high-density and high-performance application-targeted field programmable gate arrays (FPGAs). The company offers a range of products, including Speedster®22i HD devices, which feature up to 1.7 million effective look-up tables (LUTs) and 138 megabits of embedded RAM, and Speedster22i HP devices, which utilize picoPIPE architecture and provide up to 590 thousand effective LUTs with 64 megabits of embedded RAM. Achronix's Speedcore eFPGA IP allows integration into customer system-on-chips (SoCs) for compute and network acceleration. Additionally, the Achronix CAD Environment (ACE) supports FPGA design, while the HD1000 development board is optimized for networking and communication sub-systems. Achronix serves diverse markets, including networking, optical/telecom, high-performance computing, test and measurement, and military and security. Its products are distributed across North America, Europe, Israel, China, and Russia, with research and development facilities also in Bangalore, India.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
Cardiovascular Systems, Inc. specializes in developing and marketing innovative medical technologies aimed at treating peripheral and coronary vascular diseases. The company focuses on providing solutions for challenging conditions such as peripheral arterial disease (PAD) and coronary artery disease (CAD), particularly those complicated by calcium buildup. Its primary offerings include catheter-based platforms designed to address plaque in leg arteries and orbital atherectomy systems utilized in both peripheral and coronary applications. Notable products include the Diamondback 360 Peripheral and Stealth 360 systems. The majority of the company's revenue is generated from sales of its peripheral artery disease systems, predominantly within the United States. Through a commitment to clinical excellence and continuous innovation, Cardiovascular Systems aims to enhance patient outcomes and set industry standards in medical devices.
Promedior, Inc. is a clinical-stage biotechnology company based in Lexington, Massachusetts, focused on developing therapeutics for rare fibrotic diseases, such as idiopathic pulmonary fibrosis and myelofibrosis, as well as retinal fibrovascular diseases like age-related macular degeneration and diabetic retinopathy. The company has created a drug discovery platform that targets monocyte-derived cell populations involved in fibrotic, inflammatory, and autoimmune diseases. By addressing the source of abnormal immune responses, Promedior aims to promote tissue healing while minimizing systemic side effects associated with existing therapies. Its main products include PRM-151, a recombinant form of human pentaxin-2 protein for intravenous injection, and PRM-167, designed for intravitreal delivery. Promedior was previously known as Fibrotix, Inc. and has been a subsidiary of Roche Holding AG since February 2020.
IGA serves advertisers and video game publishers looking to include marketing messages within console and PC games. IGA's roster of publisher partners includes [Electronic Arts](http://www.crunchbase.com/organization/electronic-arts), Valve, and Atari among others. The company competes with [Massive](http://www.crunchbase.com/organization/massive) and [AdScape](http://www.crunchbase.com/organization/adscape), two video game ad agencies that were acquired by [Microsoft](http://www.crunchbase.com/organization/microsoft) and [Google](http://www.crunchbase.com/organization/google) respectively.
Sonics is a leading provider of network-on-chip (NoC) technology, specializing in intelligent on-chip communications solutions for various applications, including home entertainment, wireless networking, and mobile devices. Established in 1996 and headquartered in Milpitas, California, the company offers a comprehensive portfolio of silicon-proven intellectual property (IP) that addresses the memory bottlenecks and data flow challenges associated with complex, high-speed system-on-chip (SoC) designs. By enabling heterogeneous, multi-core SoC architectures, Sonics integrates essential subsystems, such as security, power, and memory, to deliver high performance and low power consumption. Its innovative technology has facilitated the shipment of over 750 million units globally, positioning Sonics as a key player in the embedded market.
Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.
Sonics is a leading provider of network-on-chip (NoC) technology, specializing in intelligent on-chip communications solutions for various applications, including home entertainment, wireless networking, and mobile devices. Established in 1996 and headquartered in Milpitas, California, the company offers a comprehensive portfolio of silicon-proven intellectual property (IP) that addresses the memory bottlenecks and data flow challenges associated with complex, high-speed system-on-chip (SoC) designs. By enabling heterogeneous, multi-core SoC architectures, Sonics integrates essential subsystems, such as security, power, and memory, to deliver high performance and low power consumption. Its innovative technology has facilitated the shipment of over 750 million units globally, positioning Sonics as a key player in the embedded market.
Zalicus Inc., based in Cambridge, Massachusetts, is a biopharmaceutical company focused on developing innovative drug candidates for the treatment of pain and inflammation. The company specializes in ion-channel modulation, which involves creating therapeutics that selectively block ion channels in neuronal cells to disrupt pain signal transmission. Zalicus has dedicated significant resources to drug discovery technology, conducting both preclinical and clinical trials, and protecting its intellectual property. Notably, the company received FDA approval for Exalgo, an extended-release formulation of hydromorphone, designed for managing moderate to severe pain in patients who are opioid tolerant. Additionally, Zalicus aims to discover and develop novel-target pain therapies, including calcium channel modulators for both chronic and acute inflammatory pain. The company's evolution includes a merger with Neuromed Pharmaceuticals, enhancing its capabilities in pain management.
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.
Conor MedSystems specializes in the development of controlled drug delivery technologies for vascular applications, primarily focusing on drug-eluting stents designed to treat coronary artery disease and restenosis. The company aims to enhance the effectiveness of vascular stents by incorporating mechanisms that allow for localized drug delivery to both coronary and peripheral vessels. Through its innovative approach, Conor MedSystems seeks to improve patient outcomes in the management of vascular conditions.
Renovis, Inc. is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The Company is currently developing products for acute ischemic stroke, for the treatment of neuropathic pain, and for the treatment of acute post-operative pain.
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI) and other disorders of the nervous system. The first product for which the Company completed clinical development, Ampyra (dalfampridine) Extended Release Tablets (Ampyra), was approved by the United States Food and Drug Administration (FDA) in January 2010, as a treatment to improve walking in patients with MS. Ampyra is an extended-release tablet formulation of dalfampridine (4-aminopyridine (4-AP)), which was previously referred to as fampridine. Acorda's marketed product, Zanaflex Capsules, is approved by the FDA as a short-acting drug for the management of spasticity.
Catalyst Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative treatments for hemophilia and other rare bleeding disorders. The company focuses on engineered subcutaneous coagulation factors that enhance blood clotting, aiming to improve patient outcomes compared to traditional intravenous treatments. Its key products include Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II trials for patients with hemophilia A or B with inhibitors, and Dalcinonacog alfa, an engineered Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Catalyst is also developing early-stage gene therapy constructs and long-acting anti-C3 proteases for conditions such as dry age-related macular degeneration (AMD). The company collaborates with Mosaic Biosciences to create anti-complement factor 3 products for retinal diseases and has a partnership with Biogen for the commercialization of pegylated anti-C3 protease therapies. Founded in 2002, Catalyst Biosciences is dedicated to establishing protease therapeutics as a significant new therapeutic platform.
Conor MedSystems specializes in the development of controlled drug delivery technologies for vascular applications, primarily focusing on drug-eluting stents designed to treat coronary artery disease and restenosis. The company aims to enhance the effectiveness of vascular stents by incorporating mechanisms that allow for localized drug delivery to both coronary and peripheral vessels. Through its innovative approach, Conor MedSystems seeks to improve patient outcomes in the management of vascular conditions.
Sonics is a leading provider of network-on-chip (NoC) technology, specializing in intelligent on-chip communications solutions for various applications, including home entertainment, wireless networking, and mobile devices. Established in 1996 and headquartered in Milpitas, California, the company offers a comprehensive portfolio of silicon-proven intellectual property (IP) that addresses the memory bottlenecks and data flow challenges associated with complex, high-speed system-on-chip (SoC) designs. By enabling heterogeneous, multi-core SoC architectures, Sonics integrates essential subsystems, such as security, power, and memory, to deliver high performance and low power consumption. Its innovative technology has facilitated the shipment of over 750 million units globally, positioning Sonics as a key player in the embedded market.
ModelWire specializes in software solutions tailored for the modeling and fashion industry, offering digital tools that enable model and talent agents to advertise and book their clients efficiently. The platform serves a diverse clientele, including advertising agencies, photographers, catalog publishers, and magazines, providing them with comprehensive resources for managing their operations. ModelWire's features encompass imaging, packaging, online booking, and invoicing, all accessible around the clock. As a global leader in online model management, ModelWire aims to enhance productivity and streamline workflows for agents, supporting their success in a competitive industry. ModelWire operates under the umbrella of Geyser Technologies.
Worldo, a vertical industry portal for commercial architectural interiors.
Jarg Corporation, founded in 1997 and based in Waltham, Massachusetts, specializes in developing advanced search engine technologies that enhance the quality of search results by embedding search terms in context. The company offers a Semantic Knowledge Indexing Platform, which is designed for licensing to application developers, enabling them to create innovative knowledge discovery applications. Jarg's distributed indexing platform leverages graph-based data and semantic content to improve information retrieval, thereby increasing productivity for knowledge workers and providing a competitive edge for businesses. Their technology is adaptable to various forms of digital content and is built on over fifteen years of research and development in the field of information retrieval.